Immunoglobulin E–independent Major Histocompatibility Complex–restricted T Cell Peptide Epitope–induced Late Asthmatic Reactions
暂无分享,去创建一个
[1] S. Durham,et al. Effect of cyclosporin A on the allergen-induced late asthmatic reaction. , 1997, Thorax.
[2] A. Kay,et al. Randomised, dose-ranging, placebo-controlled study of chimeric antibody to CD4 (keliximab) in chronic severe asthma , 1998, The Lancet.
[3] F. Simons,et al. Fel d 1 peptides: effect on skin tests and cytokine synthesis in cat-allergic human subjects. , 1996, International immunology.
[4] R. Jordon,et al. ITS DEPENDENCE UPON IgE ANTIBODIES , 1976 .
[5] R. Zinkernagel,et al. H-2 compatability requirement for T-cell-mediated lysis of target cells infected with lymphocytic choriomeningitis virus. Different cytotoxic T- cell specificities are associated with structures coded for in H-2K or H-2D; , 1975, The Journal of experimental medicine.
[6] P. Moseley,et al. Local allergen challenge and bronchoalveolar lavage of allergic asthmatic lungs. Description of the model and local airway inflammation. , 1987, The American review of respiratory disease.
[7] S. Durham,et al. Increases in activated T lymphocytes, eosinophils, and cytokine mRNA expression for interleukin-5 and granulocyte/macrophage colony-stimulating factor in bronchial biopsies after allergen inhalation challenge in atopic asthmatics. , 1993, American journal of respiratory cell and molecular biology.
[8] J. Rothbard,et al. Peptides recognized by class I restricted T cells also bind to MHC class II molecules. , 1990, International immunology.
[9] G. Solley,et al. The late phase of the immediate wheal and flare skin reaction. Its dependence upon IgE antibodies. , 1976, The Journal of clinical investigation.
[10] F. Hargreave,et al. Late cutaneous allergic responses in isolated IgE-dependent reactions. , 1973, The Journal of allergy and clinical immunology.
[11] C. Corrigan,et al. CD4 T-lymphocyte activation in acute severe asthma. Relationship to disease severity and atopic status. , 1990, The American review of respiratory disease.
[12] J. Greenstein,et al. Peripheral T-cell tolerance induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[13] P. Kuna,et al. Characterization of the human basophil response to cytokines, growth factors, and histamine releasing factors of the intercrine/chemokine family. , 1993, Journal of immunology.
[14] A. Kay,et al. Eosinophil activation and T lymphocyte infiltration in allergen-induced late phase skin reactions and classical delayed-type hypersensitivity. , 1991, Journal of immunology.
[15] J. Lamb,et al. Regulation of house dust mite responses by intranasally administered peptide: transient activation of CD4+ T cells precedes the development of tolerance in vivo. , 1996, International immunology.
[16] L. Picker,et al. Circulating allergen-reactive T cells from patients with atopic dermatitis and allergic contact dermatitis express the skin-selective homing receptor, the cutaneous lymphocyte-associated antigen , 1995, The Journal of experimental medicine.
[17] A. Wardlaw,et al. Eosinophils: biology and role in disease. , 1995, Advances in immunology.
[18] C. Corrigan,et al. T cells and eosinophils in the pathogenesis of asthma. , 1992, Immunology today.
[19] S. Durham,et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. , 1992, The New England journal of medicine.
[20] J. Drazen,et al. T-lymphocytes regulate genetically determined airway hyperresponsiveness in mice , 1997, Nature Medicine.
[21] D. Huston,et al. Enhanced detection of human IL-5 in biological fluids utilizing murine monoclonal antibodies which delineate distinct neutralizing epitopes. , 1994, Cytokine.
[22] S. Durham,et al. Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. , 1990, The American review of respiratory disease.
[23] S. Durham,et al. Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. , 1997, Journal of immunology.
[24] J. Morgenstern,et al. Potential therapeutic recombinant proteins comprised of peptides containing recombined T cell epitopes. , 1994, Molecular immunology.
[25] J. Martin,et al. Transfer of allergic airway responses with antigen-primed CD4+ but not CD8+ T cells in brown Norway rats. , 1995, The Journal of clinical investigation.
[26] K. B. Hafner,et al. Treatment of cat allergy with T-cell reactive peptides. , 1996, American journal of respiratory and critical care medicine.
[27] J. Bousquet,et al. Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats. , 1998, The Journal of allergy and clinical immunology.
[28] R. Zinkernagel,et al. H-2 compatibility is required for T-cell-mediated lysis of target cells infected with lymphocytic choriomeningitis virus , 1975, The Journal of experimental medicine.
[29] C. Corrigan,et al. T LYMPHOCYTE ACTIVATION IN ACUTE SEVERE ASTHMA , 1988, The Lancet.